ARA-290 vs BPC-157
Side-by-side comparison of ARA-290 and BPC-157: mechanism, half-life, dose range, safety profile, and vendor pricing.
Price snapshot
ARA-290
BPC-157
ARA-290
ARA-290, also known as Cibinetide or pHBSP (Helix B Surface Peptide), is an 11-amino-acid peptide — QEQLERALNSS — designed to mimic a specific region of the tissue-protective surface of erythropoietin (EPO) without…
Lowest listed price: $32.00 across 5 listings
Full ARA-290 profileBPC-157
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids (Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val) derived from a partial sequence of human gastric juice…
Lowest listed price: $34.99 across 15 listings
Full BPC-157 profileSide-by-side comparison
| Attribute | ARA-290 | BPC-157 |
|---|---|---|
| Category | Recovery | Injury, Repair & Recovery |
| Research Stage | Phase 2 | Preclinical |
| Mechanism of Action | ARA-290's mechanism of action is one of the more elegantly engineered examples of pharmaceutical design in the peptide space. Understanding it requires appreciation of the dual-receptor biology of erythropoietin and the specific receptor-selective engineering… | Nitric Oxide (NO) System Modulation BPC-157 exerts a central integrative effect through modulation of the nitric oxide system. Studies by Seiwerth et al. (2022) demonstrated that BPC-157 counteracts both NO-excess and NO-deficiency states, functioning as a… |
| Half-Life | ~2 minutes (plasma half-life; downstream tissue-protective effects persist hours to days) | Short plasma half-life. The first formal preclinical ADME study reported an elimination half-life under ~30 minutes after IV/IM dosing in rats and dogs, with linear dose-proportional kinetics (PMID: 36588717); a 2026 biopharmaceutical review confirms this sub-30-minute plasma half-life and highlights a pharmacokinetic-pharmacodynamic disconnect, as biological effects persist for hours to days (PMID: 42198317). No full human pharmacokinetic study has been published; twice-daily dosing is empirical/community-standard rather than PK-derived. |
| Typical Dose Range | 1 mg - 4 mg subcutaneous daily | 200-500 mcg subcutaneous 1-2x daily (community protocols); 1-10 mcg/kg in animal studies |
| Dosing Frequency | Once daily | Twice daily (AM and PM) for optimal serum levels; once daily acceptable |
| Administration | — | Subcutaneous, Oral, Intraperitoneal, Intravenous |
| Side Effects | ARA-290 has demonstrated a notably favorable safety profile across clinical trials — one of the cleaner safety records among research peptides. The engineering rationale of separating tissue-protective effects from hematopoietic effects appears to have largely… | Generally well-tolerated. Mild nausea or GI discomfort during initial use. Temporary increase in pain/inflammation at injury site (healing response). Rare: drowsiness, dizziness, mild headache. Very rare: transient changes in blood pressure. |
| Molecular Weight | ~1257 Da | 1419.5 g/mol (average); molecular formula C62H98N16O22 |
| Common Vial Sizes | — | 5mg, 10mg |
Price History
3 data points- Ion Peptide
- BHG Labs
- LB
Price History
7 data points- OF
- BM
- Half Nattys
- LB
- Ion Peptide
- BHG Labs
ARA-290: potential benefits
- Neuroprotective effects
- Anti-inflammatory activity
- Tissue repair without erythropoiesis
- Potential diabetic neuropathy treatment
- Sarcoidosis symptom reduction
BPC-157: potential benefits
- Accelerated tendon and ligament healing with improved biomechanical strength in preclinical soft-tissue injury models (PMID: 30915550)
- Gastric and GI mucosal cytoprotection against ethanol-induced lesions, mediated in part by the nitric oxide system (PMID: 30279308)
- Healing of cysteamine-induced colitis and colon anastomosis in preclinical inflammatory bowel disease models (PMID: 24304574)
- Neuroprotection with dopaminergic and nitric oxide-system modulation in central nervous system injury models such as stroke and dopamine-receptor blockade (PMID: 34380875)
- Promotion of angiogenesis via VEGFR2 up-regulation, internalization, and VEGFR2-Akt-eNOS signaling in rat hind-limb ischemia and endothelial assays (PMID: 27847966)
- Tendon fibroblast outgrowth, cell survival, and migration through FAK-paxillin pathway activation (PMID: 21030672)
- Growth hormone receptor up-regulation in tendon fibroblasts, potentiating growth hormone's proliferative effect (PMID: 25415472)
- Nitric oxide-system interaction with endothelium protection, angiogenesis, and EGR-1-mediated growth-factor and collagen expression (PMID: 22300085)
Frequently asked
What's the difference between ARA-290 and BPC-157?
ARA-290 is a recovery that ara-290's mechanism of action is one of the more elegantly engineered examples of pharmaceutical design in the peptide space. understanding it requires appreciation of the…. BPC-157 is a injury, repair & recovery that nitric oxide (no) system modulation bpc-157 exerts a central integrative effect through modulation of the nitric oxide system. studies by seiwerth et al. (2022) demonstrated that…. The two differ in mechanism, half-life (~2 minutes (plasma half-life; downstream tissue-protective effects persist hours to days) vs Short plasma half-life. The first formal preclinical ADME study reported an elimination half-life under ~30 minutes after IV/IM dosing in rats and dogs, with linear dose-proportional kinetics (PMID: 36588717); a 2026 biopharmaceutical review confirms this sub-30-minute plasma half-life and highlights a pharmacokinetic-pharmacodynamic disconnect, as biological effects persist for hours to days (PMID: 42198317). No full human pharmacokinetic study has been published; twice-daily dosing is empirical/community-standard rather than PK-derived.), and typical dose range.
Which has the longer half-life, ARA-290 or BPC-157?
ARA-290 has a half-life of ~2 minutes (plasma half-life; downstream tissue-protective effects persist hours to days). BPC-157 has a half-life of Short plasma half-life. The first formal preclinical ADME study reported an elimination half-life under ~30 minutes after IV/IM dosing in rats and dogs, with linear dose-proportional kinetics (PMID: 36588717); a 2026 biopharmaceutical review confirms this sub-30-minute plasma half-life and highlights a pharmacokinetic-pharmacodynamic disconnect, as biological effects persist for hours to days (PMID: 42198317). No full human pharmacokinetic study has been published; twice-daily dosing is empirical/community-standard rather than PK-derived.. Longer half-lives generally mean less frequent dosing but slower on/off kinetics.
Which is cheaper, ARA-290 or BPC-157?
Lowest listed price on BodyHackGuide: ARA-290 from $32.00, BPC-157 from $34.99. Prices are pulled from the vendor listings tracked on BHG and change frequently. See the compare tables on each compound page for the current set of offers.
Can you stack ARA-290 and BPC-157?
Stacking depends on mechanism overlap, safety profile, and goals. ARA-290 and BPC-157 should only be stacked after reviewing each compound's individual protocol page, side effect profile, and any published interaction data. Use the BodyHackGuide stack builder for a structured review before combining research compounds.
See current vendor prices
Listings from the vendors we track. Prices change often, so check the vendor before you buy.
Before you buy ARA-290 or BPC-157
Check the vendor trust score. Every supplier we track is rated 0-100 on COA verification, payment transparency, shipping, reviews, and listings: one published, reproducible methodology, applied to every vendor.
Related comparisons
Research use only. BodyHackGuide is a research and price-comparison reference. The compounds discussed on this page are not approved by the FDA for human consumption and are sold strictly for laboratory research. Prices shown are pulled from vendor listings tracked on BHG and are subject to change. We earn an affiliate commission on some outbound clicks, and every vendor is ranked on the same public, reproducible methodology. See editorial standards and affiliate disclosure.